The committees will focus on defining the condition of POP. It will include topics on the epidemiology/pathophysiology of POP (including genetics to risk factors), clinical definition of the disease state and patients’ perceptions of disease burden and therapeutic success.


The duration of the commitment is 3 years. The committees were formed in 2018 and have begun working together. Each committee met in person at the IUGA/AUGS Joint Scientific in Nashville in September 2019. A private meeting room was provided for a half day (4 hours) to finalize the scope of the report. After the scope of the report was finalized, each committee presented their ideas to the attendees of the Annual Meeting at a dedicated consultation session on Friday, September 27. Each committee had 10 minutes to present their ideas followed by 5 minutes of questions and discussion with the audience.

After the consultation sessions at the Annual Meeting, the committee now has 12 months to finalize their recommendations and write the manuscript. This final work may be presented by the committee at the IUGA Annual Meeting in The Hague in 2020. Immediately following the Annual Meeting, the final manuscript will be submitted to the IUJ in 2020 with the aim to be published in the beginning of 2021.


1. Clinical Definition of POP
This report will discuss how the mechanisms of vaginal birth and age predispose women to develop pelvic organ prolapse. The impact of pregnancy, the mechanics of the delivery process and enzymatic and protein alterations or deficiencies will be reviewed and their contribution to the process of developing pelvic organ prolapse will be discussed. What is known about how genetics and family history contribute to these processes will be discussed looking for potential risk factors for developing pelvic organ prolapse.

Steering Committee Advisor     
TS Lo (Taiwan)

Committee Chair                     
Kimberly Kenton (USA)

Committee Members
Tiffany Chih (USA)
Sarah Collins (USA)
Kim van Delft (The Netherlands)
Nicola Dykes (New Zealand)
Autumn Edenfield (USA)
Cheng-Yu Long (Taiwan)
Michele O'Shea (USA)

Olga Ramm (USA)
Clara Shek (Australia)

2. Epidemiology of Pelvic Organ Prolapse: Incidence/Prevalence, Natural History
This will be the first report for this section and will set the tone for this entire report. Defining the disease and how symptoms and physical exam findings play a role in an accurate definition of the disease state of pelvic organ prolapse. This committee should seek to develop a clinically useful definition of this disease based on what is known about normal support vs abnormal support and how the interaction of physical exam findings relates to pelvic organ prolapse specific symptoms. 

Steering Committee Advisor    
Lynsey Hayward (New Zealand)

Committee Chair
Heidi Brown (USA)         

Committee Members
Aparna Hegde (India)
Markus Huebner (Switzerland)
Ervin Kocjancic (USA)
Gisele Vissoci Marquini (Brazil)
Bernard Mbwele (Tanzania)
Hedwig Neels (Belgium)
Visha Tailor (United Kingdom)
Elisa Trowbridge (USA)

3. Pathophysiology of Pelvic Organ Prolapse: Risk Factors, Family History, Genetic Mutations
This report will focus on the how many women are affected with pelvic organ prolapse, the lifetime risk of developing pelvic organ prolapse and how untreated pelvic organ prolapse progresses or regresses. This will set the tone going forward by giving the overall impact of pelvic organ prolapse as a disease in women. There should be discussion of the future need for services, particularly surgical care of prolapse as the population ages. This reports can touch on definitions  (symptomatic definitions vs physical exam definitions) and how this relates to the various reports on incidence, prevalence and natural history, but should not express opinions on which definition is most appropriate (that will precede this report in the chapter on the definition). The committee chairs will coordinate their writing so that terminology in this report is consistent with the report on the Definition of Pelvic Organ Prolapse.

Steering Committee Advisor
Maria Bortolini (Brazil)

Committee Chair
Jan Deprest (Belgium)

Committee Members
Kristina Allen-Brady (USA)
Vivian Aguilar (USA)
Luiz Gustavo Oliveira Brito (Brazil)
Rufus Cartwright (United Kingdom)
Hans Peter Dietz (Australia)
Marianne Koch (Austria)
Jittima Manonai (Thailand)
Adi Weintraub (Israel)

4. Patients' Perception of Disease Burden of POP
This report will focus on how women perceive pelvic organ prolapse and its relationship to body image and poor health.  How the vaginal bulge affects women’s sense of health and wellbeing and how women perceive benefit from treatment will be reviewed. This report will attempt to best define what aspects of pelvic organ prolapse have the greatest impact on women’s sense of wellbeing so that appropriate treatment goals can be established. The cost to society of treating pelvic organ prolapse will be covered in this chapter. The chair of this report will coordinate with the chair of the report on Relationship to Associated Morbidity/Pelvic Floor Dysfunction Prolapse to assure consistency as there will be some overlap of these reports.

Steering Committee Advisor
Chantal Dumoulin (Canada)

Committee Chair
Dudley Robinson (United Kingdom)

Committee Members
Symphorosa Chan (Hong Kong)
Chiara Ghetti (USA)
Suzanne Hagen (United Kingdom)
Jerry Lowder (USA)
Svjetlana Lozo (USA)
Kathie Hullfish USA
Lisa Prodigalidad (Philippines)
Maurizio Serati (Italy)

5. Relationship to Associated Morbidity/Pelvic Floor Dysfunction (Urinary Incontinence/Voiding Dysfunction, Fecal Incontinence, Sexual Dysfunction and Pelvic Pain)
This report will focus on comorbid conditions that commonly impact women with pelvic organ prolapse. Vaginal/lower abdominal/back pain, sexual dysfunction, lower and upper urinary tract disease and gastrointestinal dysfunction will be discussed and their prevalence in women with pelvic organ prolapse defined. How these comorbid conditions affect health and treatment planning will be briefly reviewed. Treatment of these co-morbid conditions will follow in subsequent reports dedicated to treatment and will not be discussed in depth in this report. The chair of this report will coordinate with the chair of the report on Patients Perception of Disease, Quality of Life and Disease Burden to assure consistency as there will be some overlap of these reports.

Steering Committee Advisor
Bob Freeman (United Kingdom)

Committee Chair
Marie-Andree Harvey (Canada)

Committee Members
Alexandriah Alas (USA)
Baharak Amir (Canada)
Alka Bhide (United Kingdom)
Roxana Geoffrion (Canada)
Pawel Miotla (Poland)
Ifeoma Offiah (United Kingdom)
Manidip Pal (India)
Peter Rosier (The Netherlands)